Unicycive Therapeutics (UNCY) Debt Ratio (2020 - 2024)

Unicycive Therapeutics' (UNCY) quarterly Debt Ratio came in at 0.0 in Q1 2024, down 23.74% on a QoQ basis from 0.01 in Q3 2021.

Unicycive Therapeutics (UNCY) Debt Ratio (2020 - 2024) Analysis & Trends

Unicycive Therapeutics (UNCY) has 3 years of Debt Ratio data on file, last reported at 0.0 in Q1 2024.

Quarterly Debt Ratio changed N/A year-over-year to 0.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was 0.0 (changed N/A YoY) and the FY2020 annual result came in at 4.74, changed N/A from the prior year.
Debt Ratio slipped to 0.0 in Q1 2024, from 0.01 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 4.74 in Q4 2020 to a low of 0.0 in Q1 2024.
A 3-year average of 1.43 and a median of 0.5 in 2021 frame the typical range for Debt Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Unicycive Therapeutics	151.01 Mn	151.01 Mn	-	-

Download Data